NASDAQ · Biotechnology

IGM Biosciences, Inc. (IGMS) Stock

$1.27 +0.00% NASDAQ: IGMS Healthcare

IGM Biosciences, Inc. operates as a biotechnology firm dedicated to advancing Immunoglobulin M (IgM) antibodies.

Valuation

MetricValue
Price$1.27
Market Cap$77.50M
P/E Ratio1.75
P/B Ratio0.77
P/S Ratio0.54
EPS (TTM)$0.73
52-Week High$22.50
52-Week Low$0.92
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE87.95%
ROA41.77%
ROCE74.82%
Gross Margin99.69%
Operating Margin52.40%
Net Margin31.01%
Debt/Equity0.94
Current Ratio17.66

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$1.0M$2.0M$3.0M
Operating Profit$-83.0M$-165.0M$-228.0M$-263.0M$-209.0M
Net Profit$-80.0M$-161.0M$-214.0M$-246.0M$-196.0M
EPS$-2.61$-4.80$-5.16$-4.71$-3.24
Op Margin——-21324.2%-12369.1%-7785.7%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$409.0M$298.0M$513.0M$423.0M$266.0M
Total Liabilities$27.0M$53.0M$226.0M$220.0M$218.0M
Cash$241.0M$133.0M$121.0M$113.0M$26.0M
Borrowings$12.0M$29.0M$41.0M$41.0M$45.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-67.0M$-124.0M$-6.0M$-192.0M$-153.0M
Investing Cash Flow$40.0M$2.0M$-236.0M$137.0M$58.0M
Financing Cash Flow$-1.0M$1.0M$1.0M$2.0M$2.0M
Net Cash Flow$205.0M$-107.0M$-12.0M$-9.0M$-86.0M
Free Cash Flow$-85.0M$-138.0M$-16.0M$-205.0M$-159.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA0.69
FCF Yield-107.54%
Quick Ratio17.66
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About IGM Biosciences, Inc.

IGM Biosciences, Inc. operates as a biotechnology firm dedicated to advancing Immunoglobulin M (IgM) antibodies. These novel therapeutic agents are being developed for a broad spectrum of conditions, including various cancers, infectious ailments, and autoimmune and inflammatory disorders. The company's most advanced experimental treatment is IGM-2323, a bispecific IgM antibody. This candidate is currently in Phase 2 clinical trials, evaluating its efficacy for patients diagnosed with relapsed or refractory B cell Non-Hodgkin's lymphoma (NHL). In addition to its lead program, IGM Biosciences maintains an active pipeline of other IgM antibodies. IGM-8444, an IgM antibody, is presently undergoing Phase 1 clinical trials for solid cancers. Another therapy in development, IGM-7354, is an anti-PD-L1 IgM antibody targeting both solid and hematologic malignancies. The company is also progressing IGM-2644, a bispecific T cell engaging IgM antibody designed to target CD38 and CD3 proteins, intended for individuals with multiple myeloma. Furthermore, IGM-2537, another bispecific T cell engaging IgM antibody, aims to target CD123 and CD3 proteins for potential use in acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences has a strategic collaboration and licensing arrangement with Genzyme Corporation. This partnership encompasses the generation, development, manufacturing, and commercialization of IgM antibodies. The company, initially founded in 1993 as Palingen, Inc., changed its name to IGM Biosciences, Inc. in 2010. Its corporate headquarters are located in Mountain View, California.

IGM Biosciences, Inc. is headquartered in US.

IGM Biosciences, Inc. (IGMS) stock trades at $1.27 with a market capitalization of $77.50M. The stock is valued at a price-to-earnings (P/E) ratio of 1.75, price-to-book of 0.77, price-to-sales of 0.54. Over the past 52 weeks the stock has ranged between $0.92 and $22.50, and currently trades 94.4% below its 52-week high.

On profitability, IGM Biosciences, Inc. generates a return on equity (ROE) of 87.95% — well above the market average, a sign of a high-quality business, return on capital employed of 74.82%, an operating margin of 52.40%, a net profit margin of 31.01%.

Official website: igmbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides